Alnylam Pharmaceuticals (ALNY) PT Raised to $270 at Goldman Sachs
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $225.14 +0.53%
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 15 | New: 9
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 15 | New: 9
Join SI Premium – FREE
Goldman Sachs analyst Salveen Richter raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $270.00 (from $239.00) while maintaining a Buy rating.
You May Also Be Interested In
- Hyperion DeFi, Inc. (HYPD) PT Raised to $7.10 at Cantor Fitzgerald
- Kontoor Brands (KTB) PT Raised to $136 at UBS on Long-Term Opportunities
- Trimble Navigation (TRMB) PT Lowered to $73 at Bernstein SocGen Group
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
